Phase I Study of Episcleral Celecoxib for Treatment of Macular Edema &

Status Active, not recruiting

Clinical Trial Summary

This phase I trial will assess primarily the safety and secondarily the anti-inflammatory and anti-neovascular effect of Episcleral Celecoxib in patients suffering from macular edema and other inflammatory disorders of the retina, choroid and vitreous.

Clinical Trial Description

This phase I trial will assess primarily the safety and secondarily anti-inflammatory/neovascular effect of Episcleral Celecoxib in patients suffering from macular edema & inflammatory disorders of the eye posterior pole Including sclera, choroid, retina, or vitreous. Celecoxib is a specific cyclooxygenase-2 inhibitor that possesses anti-angiogenic, anti-inflammatory, and anti-fibrotic properties. Non-clinical studies have documented the activity of Celecoxib in reducing leakage of the blood-retina barrier as well as inhibiting vascular endothelial growth factor (VEGF) and prostaglandin E2 (PGE2) expression in the retina of diabetic rats. The underlying mechanisms for its anti-inflammatory and anti-angiogenic properties have been extensively characterized. The investigators hypothesize that Episcleral Celecoxib is safe, tolerable and that its anti-inflammatory/anti-neovascular activity will reduce macular edema and improve vision in patients with macular edema. Objective: to primarily assess the safety, tolerability and pharmacokinetics of Episcleral Celecoxib in patients with macular edema and other inflammatory disorders of the posterior pole including retina, choroid and vitreous to secondarily assess efficacy in reducing macular edema and improving visual function. Methods: The main outcome of the study is safety assessment. Secondary outcomes are assessment of visual acuity and anatomical changes in the macula as measured via optical coherence tomography (OCT). ;

Study Design

Related Conditions & MeSH terms

Branch Retinal Vein Occlusion
Central Serous Chorioretinopathy
Central Serous Retinopathy With Pit of Optic Disc
Commotio Retinae
Edema
Epiretinal Membrane
Macula Edema
Macular Edema
Radiation Retinopathy
Retinal Diseases
Retinal Vein Occlusion
Vitritis

Clinical Trial Details

NCT number	NCT04120636
Study type	Interventional
Source	Targeted Therapy Technologies, LLC
Contact
Status	Active, not recruiting
Phase	Phase 1
Start date	March 5, 2021
Completion date	June 30, 2024

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT03332758` - Inflammasomes in Cell Death in FTMH, ERM, and RRD
Active, not recruiting	`NCT04130841` - Effects of Internal Limiting Membrane Peeling on Visual Function in Epiretinal Membrane Surgery	N/A
Recruiting	`NCT03713268` - Intraoperative OCT Guidance of Intraocular Surgery II
Terminated	`NCT01532765` - Randomized Trial Comparing Epiretinal Membrane Surgery With and Without Internal Limiting Membrane Removal	N/A
Completed	`NCT01474655` - Retinal Layers and Visual Rehabilitation After Epiretinal Membrane Removal	N/A
Active, not recruiting	`NCT04120311` - Episcleral Dexamethasone for Treatment of Macular Edema and Inflammatory Disorders of the Posterior Pole	Phase 1
Completed	`NCT04445142` - Fovea ERM After Fovea-sparing ILM Peeling
Recruiting	`NCT01701518` - A Pilot Study of the Effectiveness of Intra-operative Ozurdex® in Vitrectomy Surgery for Epiretinal Membranes	N/A
Completed	`NCT01627977` - Association of Lutein, Zeaxanthin and Brilliant Blue in Chromovitrectomy	Phase 3
Completed	`NCT01771939` - Phacoemulsification and 25 Gauge (25G) Vitrectomy Versus Phacoemulsification Only in Idiopathic Epiretinal Membranes	N/A
Completed	`NCT00408720` - Comparison of a Spectral OCT/SLO With the Stratus OCT for Imaging Various Retinal Pathologies	N/A
Completed	`NCT05171621` - Measuring Subjective Quality of Vision and Metamorphopsia Before and After Epiretinal Membrane and Macular Hole Surgery
Active, not recruiting	`NCT04306718` - Cultivation of Hyalocytes From ILM and ERM Samples: a Pilot Study	N/A
Recruiting	`NCT01985490` - Change in Foveal Avascular Zone After Removal of Epiretinal Membrane and Internal Limiting Membrane	N/A
Completed	`NCT01238393` - Treatment of Epiretinal Membranes With Ranibizumab	N/A
Terminated	`NCT00333060` - Study of OT-551 Eye Drops to Prevent or Delay Progression of Nuclear Cataracts Following Vitreous Removal	Phase 2
Completed	`NCT05287269` - Ocular Coherence Tomography During Cataract Assessment
Recruiting	`NCT05138315` - Quantification of Metamorphopsia in Patients With Epiretinal Membranes	N/A
Recruiting	`NCT03661593` - Aniseikonia in Epiretinal Membrane Patients	N/A
Completed	`NCT03457584` - Effect of Air-tamponade on Intraretinal Cystoid Changes After Membrane Peeling	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Phase I Study of Episcleral Celecoxib for Treatment of Macular Edema and Inflammatory Disorders of the Posterior Pole

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms